What's new?
17/10/2019

The firm manages €2B across its life sciences platform, €1B of which has been raised in the last 4 years

Paris, France – October 17th, 2019 — Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan and specialized in Life Sciences, announced today the close of its latest early-stage healthcare venture capital fund Sofinnova Capital IX, oversubscribed at €333 million. The firm now has more than €2B under management with more than €1B raised in the last four years across its platform of life sciences funds.

Pursuing the strategy it has consistently applied over the years for its flagship early-stage Capital funds, Sofinnova Capital IX will invest in the healthcare industry and more specifically in the biopharmaceutical and medical device sectors. Sofinnova Partners will seek to invest as a founding and lead investor in start-ups and corporate spin-offs, and focus on therapeutic, paradigm-shifting technologies and products alongside visionary entrepreneurs. Sofinnova Capital IX will invest about two thirds of its funds in European companies, and one third outside of Europe, primarily in North America.

The new fund has commitments from leading institutional investors, predominantly endowment funds, insurance companies, pension funds, sovereign funds, corporates and family offices, many of whom are continuing a long and successful relationship with the Sofinnova family of Funds. The majority of commitments came in from Europe, including France, Italy, Ireland, Denmark, Germany, Switzerland, the United Kingdom and Luxembourg, but also from leading North American investors in the U.S. and Canada, as well as major investors from Asia.
Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, said, “Our experienced team, stable strategy and exit track record resonated well with investors, hence the success of our fundraising for this latest Capital fund. Over the last three years, we have completed nine remarkable exits in the portfolio for a total enterprise value of almost 4 billion euros.”

The launch of Sofinnova Capital IX follows the formation, in just the last three years, of Sofinnova Crossover I, a fund investing in pre- and post-IPO companies; Sofinnova MD Start III, a medical device acceleration fund; Sofinnova Industrial Biotech I, a fund dedicated to industrial biotech; and Sofinnova Telethon Fund I, a fund dedicated to seed investments in gene and cell therapies based out of Milan, Italy. With these focused franchises managed by dedicated specialist teams, Sofinnova Partners has established a unique and comprehensive platform of investment vehicles across the life sciences investment value chain.

Triago acted as placement agent and Clifford Chance acted as legal counsel on Sofinnova Capital IX.

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Headquartered in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
For more information, please visit: www.sofinnovapartners.com

Media Contacts:
Kate Barrette
RooneyPartners LLC
+1.212.223.0561
kbarrette@rooneyco.com

France
Anne Rein
S&I
+33 6 03 35 92 05
anne.rein@strategiesimage.com

10/07/2015

Sofinnova Partners Renewable Chemistry Start-up Award, presented at Bio World Congress on Industrial Biotechnology, recognises the most promising renewable chemistry start-up. The Top 5 companies have been selected by popular vote online and the winner will be selected at Bio World Congress on Industrial Biotechnology by an industry jury. – RESULTS HERE !

The Renewable Chemistry Start-Up Award is supported by Sustainability Consult, the leading agency for bio-economy communications and public relations.

10/07/2015

Sofinnova Partners Renewable Chemistry Start-up Award, presented at Bio World Congress on Industrial Biotechnology, recognises the most promising renewable chemistry start-up. The Top 5 companies have been selected by popular vote online and the winner will be selected at Bio World Congress on Industrial Biotechnology by an industry jury. – RESULTS HERE !

The Renewable Chemistry Start-Up Award is supported by Sustainability Consult, the leading agency for bio-economy communications and public relations.

24/06/2014

10-12 December 2014
Four Seasons, Prague, Czech Republic

Veleslavínova 1098/2a
110 00 Praha 1-Staré Mesto
Czech Republic

bohemian_summit2014

This invitation-only conference for senior executives from medical device companies in Europe, provides a private and exclusive setting for networking and partnering. The agenda will include high-level panel discussions with keynotes from industry and academic leaders, as well as social networking events.

Who Attends?
Attendance to the Bohemian Medical Device Summit is by invitation only. Invitations are limited to CEOs and senior executives from medical technology companies and senior executives with responsibility for R&D, Licensing, M&A and Business Development from major medical device manufacturers. The conference is NOT open to service providers, such as CROs, data support, consultancy companies, banks, law firms, VCs, or funding companies.

http://www.bohemiansummit.com/

24/06/2014

10-12 December 2014
Four Seasons, Prague, Czech Republic

Veleslavínova 1098/2a
110 00 Praha 1-Staré Mesto
Czech Republic

bohemian_summit2014

This invitation-only conference for senior executives from medical device companies in Europe, provides a private and exclusive setting for networking and partnering. The agenda will include high-level panel discussions with keynotes from industry and academic leaders, as well as social networking events.

Who Attends?
Attendance to the Bohemian Medical Device Summit is by invitation only. Invitations are limited to CEOs and senior executives from medical technology companies and senior executives with responsibility for R&D, Licensing, M&A and Business Development from major medical device manufacturers. The conference is NOT open to service providers, such as CROs, data support, consultancy companies, banks, law firms, VCs, or funding companies.

http://www.bohemiansummit.com/

02/05/2014

Women Innovating Together in Healthcare is a vibrant network of accomplished women who have talent in industry, medicine, research, charity and finance. Members share a deep knowledge of the life sciences and an admirable track record of success. We come together from complementary backgrounds for lively debate, inspiration, discussion of challenges, and laughter.
with-logo

02/05/2014

Women Innovating Together in Healthcare is a vibrant network of accomplished women who have talent in industry, medicine, research, charity and finance. Members share a deep knowledge of the life sciences and an admirable track record of success. We come together from complementary backgrounds for lively debate, inspiration, discussion of challenges, and laughter.
with-logo